2024
Achievement of No-to-minimal Itch and Sleep Improvement with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age with Atopic Dermatitis
Simpson E, Siri D, Chovatiya R, Shahriari M, Burnette A, Craiglow B, Brown P, Tallman A. Achievement of No-to-minimal Itch and Sleep Improvement with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age with Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s459. DOI: 10.25251/skin.8.supp.459.Peer-Reviewed Original ResearchPP-NRSPatient Oriented Eczema MeasurePhase 3 trialAtopic dermatitisWeek 8Eczema Area and Severity Index scorePeak Pruritus Numerical Rating ScaleBody surface area involvementPruritus Numerical Rating ScaleInvestigator's Global AssessmentNumerical rating scaleSurface area involvementSeverity index scoreSleep disturbanceAnalyzed post hocSleep improvementImprovement of sleepTapinarof creamEvaluate sleep disturbancesSuperior efficacySleep disturbance scoresArea involvementTapinarofItchingGlobal assessment
2023
Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
Piraccini B, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen Y, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials. JEADV Clinical Practice 2023, 3: 242-248. DOI: 10.1002/jvc2.269.Peer-Reviewed Original ResearchSevere alopecia areataSymptoms of anxietyHealth-related qualityAlopecia areataWeek 36Hair regrowthAutoimmune hair loss disorderPsychological burdenBackground Alopecia areataProportion of patientsPhase 3 trialSelective Janus kinase 1JAK-2 inhibitorHair loss disorderBaricitinib 2Nonresponder imputationMethods PatientsHADS scoresMore patientsLarge trialsHospital AnxietyDepression ScaleAA symptomsPsychosocial distressAnalysis of covariance41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata
Shapiro J, Ko J, Egeberg A, Somani N, Jedynak J, Torisu-Itakura H, Yu G, Lu N, Craiglow B. 41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata. Journal Of The American Academy Of Dermatology 2023, 89: ab127. DOI: 10.1016/j.jaad.2023.07.511.Peer-Reviewed Original ResearchScalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials
Piraccini B, Ohyama M, Craiglow B, Bewley A, Ding Y, Chen Y, Dutronc Y, Pierce E, Durand F, Mostaghimi A. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials. Journal Of Dermatological Treatment 2023, 34: 2227299. PMID: 37381691, DOI: 10.1080/09546634.2023.2227299.Peer-Reviewed Original ResearchConceptsSevere alopecia areataHealth-related qualityHair regrowthAlopecia areataMinimal regrowthBaseline Hospital AnxietyProportion of patientsPhase 3 trialDepression Scale scoresGreater improvementBaricitinib 2Daily placeboMore patientsWeek 36Hospital AnxietyTreatment allocationSkindex-16PatientsScale scoreScore changePsychological symptomsPsychological burdenAreataTrials